Business Wire

CONQUEST

4.4.2024 12:19:30 CEST | Business Wire | Press release

Share
Conquest enters the Finnish Renewable Power Market with the Acquisition of a 182MW Onshore Wind Portfolio and the implementation of a broader Strategic Partnership towards further extensions.

Conquest enters the Finnish renewable power market with the acquisition from BHM Renewables (a BHM group company) of a 182MW onshore wind portfolio developed by Winda Energy and the implementation of a broader strategic partnership towards further extensions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404783244/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Shutterstock, Wind Portfolio in Finland

Conquest, a fund manager focusing on the infrastructures of the energy transition in Europe, through its fund Conquest Infrastructure SLP – Sustainable 2, has completed the concomitant acquisitions of two wind farms developed by Winda Energy, the Finnish renewable energy developer majority-owned by Czech BHM Renewables, part of the investment firm BHM group. The two onshore wind projects have a combined capacity of 182MW. Furthermore, the cooperation encompasses additional onshore wind projects totalling 500MW.

The transaction allows Conquest to expand its renewable power platform and its footprint in the Nordics market, while maintaining a well-balanced and diversified approach towards investments targeted to the energy transition in Europe. The transaction represents an expected phased total investment of approximately 1 billion euros, to be gradually deployed between 2024 and 2028, offering a fully green investment in one of Europe’s most stable and robust economies.

The first two wind projects are at an advanced stage of development, with the first 182MW expected to reach ready-to-build by Q4 2024 and the rest expected to reach the same stage by Q4 2025. Winda Energy Oy will complete the development and manage the construction with expected start dates of commercial operations ranging from 2026 to 2028 for the portfolio.

Frederic Palanque, Founder and Managing Director of Conquest said: “Conquest is thrilled to enter, in partnership with Winda Energy, in sustainable real assets in a market recognized for its robust renewable energy fundamentals and its ambitious net zero roadmap.”

“We are happy to cooperate with Conquest, a dynamic and reliable partner on our growth journey. The transaction secures the completion of some of our flagship projects over the next years, enabling us to extend our contribution to Finland’s green energy transition.”, says Tuomas Hooli, CEO of Winda Energy.

Michal Prause, Associate Partner at BHM Renewables, said: “We are extremely pleased with the outcome of the transaction, reflecting the deep development skills, which our affiliate Winda has been demonstrating on the Finnish renewable power market over the years. We are looking forward to the strategic partnership with the highly professional asset management and investment teams of Conquest.”

ABOUT

Conquest

Established in 2012, Conquest is an alternative asset management firm invested in sustainable and long-term value stemming from European infrastructures. Conquest invests in and operates long-life, high- quality assets and businesses on behalf of its clients, which range from large institutional investors to single-family offices. With a team of 20 collaborators, based in Dublin and Paris, the firm manages assets worth circa 500 million euros and 25 investments across Europe.

www.conquest.group

BHM group

BHM group is a rapidly expending European investment firm that manages dozens of European companies in Europe. In the energy sector, BHM group is focused on investments in renewable energy sources, with an emphasis on wind and solar energy, and is active in six countries in Central Europe and Scandinavia. Due to its extensive experience and many successful projects, BHM group companies can provide comprehensive services, encompassing development, construction, and operation. BHM group focuses on long-term and stable partnerships that take into account healthy economic growth and are in line with internationally recognized standards of social responsibility and sustainability.

www.bhmgroup.eu

Winda Energy

Winda Energy Oy is a leading Finnish renewable energy project developer with its current development portfolio consisting of 3 GW of onshore wind and 1 GW of solar PV across Finland. Winda Energy has extensive experience in the renewable sector and takes projects from their initial design to the end of construction, most recently completing the construction of 200 MW of onshore wind in 2023. Winda Energy is majority owned by BHM group.

www.winda.fi

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404783244/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye